[{"id":"6418f96b-4898-467e-b98a-b6ad9306f2dd","acronym":"CARTinNS","url":"https://clinicaltrials.gov/study/NCT04561557","created_at":"2024-05-11T04:25:35.338Z","updated_at":"2024-07-02T16:35:05.599Z","phase":"Phase 1","brief_title":"Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System","source_id_and_acronym":"NCT04561557 - CARTinNS","lead_sponsor":"Tongji Hospital","biomarkers":" CD8 • IL6 • CD4","pipe":"","alterations":" ","tags":["CD8 • IL6 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Fucaso (equecabtagene autoleucel)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 09/22/2020","start_date":" 09/22/2020","primary_txt":" Primary completion: 02/22/2027","primary_completion_date":" 02/22/2027","study_txt":" Completion: 05/31/2027","study_completion_date":" 05/31/2027","last_update_posted":"2024-05-07"},{"id":"746c9607-ab29-4d33-b2b4-9e8c8d9066d6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05201118","created_at":"2022-01-21T14:58:12.727Z","updated_at":"2024-07-02T16:36:09.998Z","phase":"Phase 1","brief_title":"A Study of a Fully Human BCMA-targeting CAR (CT103A) Combined With Selinexor in Patients With Relapsed/Refractory Extramedullary Multiple Myeloma","source_id_and_acronym":"NCT05201118","lead_sponsor":"Chunrui Li","biomarkers":" IL6","pipe":"","alterations":" ","tags":["IL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xpovio (selinexor) • Fucaso (equecabtagene autoleucel)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 01/01/2022","start_date":" 01/01/2022","primary_txt":" Primary completion: 12/31/2022","primary_completion_date":" 12/31/2022","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2022-05-24"},{"id":"c12aca54-63c9-48f0-993a-2557e3534158","acronym":"FUMANBA-2","url":"https://clinicaltrials.gov/study/NCT05181501","created_at":"2022-01-06T22:53:41.226Z","updated_at":"2024-07-02T16:36:18.778Z","phase":"Phase 1","brief_title":"A Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2)","source_id_and_acronym":"NCT05181501 - FUMANBA-2","lead_sponsor":"Nanjing IASO Biotherapeutics Co.,Ltd","biomarkers":" IL6","pipe":"","alterations":" ","tags":["IL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Fucaso (equecabtagene autoleucel)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 04/01/2022","start_date":" 04/01/2022","primary_txt":" Primary completion: 04/01/2024","primary_completion_date":" 04/01/2024","study_txt":" Completion: 04/01/2039","study_completion_date":" 04/01/2039","last_update_posted":"2022-01-06"}]